Litigation Details for Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-05-31 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Parties | PAR PHARMACEUTICAL, INC. | ||
| Patents | 6,264,981; 6,720,001; 6,740,333; 6,967,028; 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785; 9,937,223; 9,981,006 | ||
| Attorneys | Brian M. Goldberg | ||
| Firms | Farnan LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Biologic Drugs cited in Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-05-31 | 1 | Complaint | United States Patent Nos. 9,375,478 (“the ‘478 Patent”), 9,687,526 (“the ‘526 Patent”), 9,744,209 (“…(“the ‘209 Patent”), 9,744,239 (“the ‘239 Patent”), 9,750,785 (“the ‘785 Patent”), and 9,937,223 (“the…the ‘223 Patent”) (collectively, “the Patents-in-Suit”). This action is based upon the Patent Laws of …copy of the ‘478 Patent is attached as Exhibit A. Par Pharmaceutical owns the ‘478 Patent. 15. …copy of the ‘526 Patent is attached as Exhibit B. Par Pharmaceutical owns the ‘526 Patent. 16. | External link to document |
| 2019-06-12 | 14 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,375.478 B1 ;US 9,687,526 B2 ;US 9,… 31 May 2018 1:18-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-11-18 | 141 | Notice of Service | Kirsch, Ph.D. regarding Infringement of U.S. Patent Nos. 9,687,526, 9,744,209, and 9,750,785 filed by Endo … 31 May 2018 1:18-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-11-18 | 142 | Notice of Service | .Ph. Concerning Invalidity of U.S. Patent Nos. 9,678,526; 9,744,209; and 9,750,785 (Confidential - Pursuant… 31 May 2018 1:18-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-11-26 | 146 | Redacted Document | (the ’209 Patent), 9,744,239 (the ’239 Patent), 9,750,785 (the ’785 Patent), 9,937,223 (the ’223 …Pat. Nos. 9,375,478, 9,744,239 and 9,937,223 (the “Dropped Patents”)). Because Par is no longer asserting…infringement of six patents—Nos. 9,375,478 (the ’478 Patent), 9,687,526 (the ’526 Patent), 9,744,209 Case…Dropped Patents, and has agreed to dismiss its claims for infringement of the Dropped Patents with prejudice…invalidity of the ’478 Patent (First and Second Counterclaims), the ’239 Patent (Seventh and Eighth | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
